Replies to post #233053 on Biotech Values

[DewDiligence]

NVO submits Ozempic NDA for weight loss:

https://www.globenewswire.com/news-release/2020/12/04/2139776/0/en/Novo-Nordisk-files-for-US-FDA-regulatory-approval-of-once-weekly-semaglutide-2-4-mg-for-weight-management.html

NVO is applying a priority-review voucher to obtain a 6-month review schedule.